Minerva Neurosciences | NERV - Net Income


Minerva Neurosciences reported $1.44M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Adma Biologics USD 49.38M 12.95M Dec/2025
ALKERMES USD -66.48M 115.82M Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cipla INR 5.55B 1.21B Mar/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
J&J USD 5.24B 119M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024